Benzinga | Nov 12, 2021 01:51PM EST

Alector Presents Encouraging New AL001 Data From The Symptomatic FTD-GRN Cohort Of INFRONT-2 Phase 2 Open-label Clinical Study

Progranulin Levels Increase to Normal Ranges

Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, IncludingGFAP, a Prognostic Marker for FTD Associated with Brain Atrophy

FTD-GRN Patients Showed a Slowing of Clinical Progression with AL001 Treatment Relative to GENFI2 Matched Control Cohort

Data from Phase 2 Study Presented at Clinical Trials of Alzheimer Disease Conference;

Management to Host Webcast to Review Results Today at 4:00 p.m. ET